Cargando…

The Current Landscape of Glioblastoma Biomarkers in Body Fluids

SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanganeh, Saba, Abbasgholinejad, Elham, Doroudian, Mohammad, Esmaelizad, Nazanin, Farjadian, Fatemeh, Benhabbour, Soumya Rahima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416862/
https://www.ncbi.nlm.nih.gov/pubmed/37568620
http://dx.doi.org/10.3390/cancers15153804
_version_ 1785087878709116928
author Zanganeh, Saba
Abbasgholinejad, Elham
Doroudian, Mohammad
Esmaelizad, Nazanin
Farjadian, Fatemeh
Benhabbour, Soumya Rahima
author_facet Zanganeh, Saba
Abbasgholinejad, Elham
Doroudian, Mohammad
Esmaelizad, Nazanin
Farjadian, Fatemeh
Benhabbour, Soumya Rahima
author_sort Zanganeh, Saba
collection PubMed
description SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. This review provides a comprehensive overview of various cancer biomarkers, including circulating tumor cells, cell-free DNA, and RNA, such as microRNA, as well as extracellular vesicles. It highlights their clinical utility in glioblastoma detection, monitoring, and prognosis. In addition, challenges and limitations in implementing liquid biopsy strategies in clinical practice are addressed. ABSTRACT: Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility.
format Online
Article
Text
id pubmed-10416862
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104168622023-08-12 The Current Landscape of Glioblastoma Biomarkers in Body Fluids Zanganeh, Saba Abbasgholinejad, Elham Doroudian, Mohammad Esmaelizad, Nazanin Farjadian, Fatemeh Benhabbour, Soumya Rahima Cancers (Basel) Review SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. This review provides a comprehensive overview of various cancer biomarkers, including circulating tumor cells, cell-free DNA, and RNA, such as microRNA, as well as extracellular vesicles. It highlights their clinical utility in glioblastoma detection, monitoring, and prognosis. In addition, challenges and limitations in implementing liquid biopsy strategies in clinical practice are addressed. ABSTRACT: Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility. MDPI 2023-07-26 /pmc/articles/PMC10416862/ /pubmed/37568620 http://dx.doi.org/10.3390/cancers15153804 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zanganeh, Saba
Abbasgholinejad, Elham
Doroudian, Mohammad
Esmaelizad, Nazanin
Farjadian, Fatemeh
Benhabbour, Soumya Rahima
The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title_full The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title_fullStr The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title_full_unstemmed The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title_short The Current Landscape of Glioblastoma Biomarkers in Body Fluids
title_sort current landscape of glioblastoma biomarkers in body fluids
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416862/
https://www.ncbi.nlm.nih.gov/pubmed/37568620
http://dx.doi.org/10.3390/cancers15153804
work_keys_str_mv AT zanganehsaba thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT abbasgholinejadelham thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT doroudianmohammad thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT esmaelizadnazanin thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT farjadianfatemeh thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT benhabboursoumyarahima thecurrentlandscapeofglioblastomabiomarkersinbodyfluids
AT zanganehsaba currentlandscapeofglioblastomabiomarkersinbodyfluids
AT abbasgholinejadelham currentlandscapeofglioblastomabiomarkersinbodyfluids
AT doroudianmohammad currentlandscapeofglioblastomabiomarkersinbodyfluids
AT esmaelizadnazanin currentlandscapeofglioblastomabiomarkersinbodyfluids
AT farjadianfatemeh currentlandscapeofglioblastomabiomarkersinbodyfluids
AT benhabboursoumyarahima currentlandscapeofglioblastomabiomarkersinbodyfluids